CAR T-Cell Therapy Brings New Hope to People With Lupus, Helping Five Patients Reach Remission

Credit: Katie Tinkler, supplied to UCLH

A medical breakthrough best known for transforming cancer care is now offering bright new hope to people living with lupus. In a recent UK trial at University College London Hospital, five patients with severe lupus nephritis entered remission after receiving CAR T-cell therapy—an outcome that may point toward a remarkable new future for treating the autoimmune disease.

For Katie Tinkler, one of the patients in the study, the change has been extraordinary. After treatment, she was able to enjoy experiences that once felt out of reach, including Alpine skiing for the first time and dancing at her daughter’s wedding.

Lupus affects around 1.5 million Americans and has long been considered incurable. The condition occurs when the immune system mistakenly attacks healthy tissue. In lupus nephritis, that attack targets the kidneys and can also involve other organs, bringing symptoms such as severe fatigue, inflammation, joint pain, and the risk of organ failure.

CAR T-cell therapy works by using a patient’s own white blood cells. These cells are collected from the blood and genetically modified so they can be redirected toward a specific target. The approach has already earned global attention in cancer treatment, where it helps the immune system recognize and attack malignant cells.

In this lupus trial, researchers tested whether the same powerful immune-reprogramming idea could help reset the body’s misguided autoimmune response.

Nine patients with lupus nephritis received the treatment at UCLH. Six were given a lower dose of CAR T-cell therapy, while three received a higher dose. Within three months, five of the lower-dose patients had gone into remission, and they remained there throughout the study’s 11-month follow-up period. The higher-dose patients are continuing to be monitored.

The results have brought encouragement to doctors and patients alike.

“These findings are truly groundbreaking and offer fresh hope to people living with lupus,” said Professor Karl Peggs, the director of UCLH’s biomedical research center, in a news release. “If these results are confirmed in larger studies, the prospect of a cure for lupus may no longer be out of reach.”

He added: “While more research is needed, the possibility that CAR T-cell therapy could deliver an immune reset and potentially free patients from the cycle of chronic autoimmune disease marks a remarkable step forward.”

Tinkler told The Guardian that before remission, her lungs, heart, and kidneys were all declining. Now, the difference in her life feels profound.

“My life two years ago versus now, it’s unrecognizable. I feel blessed.”

The findings are still early, and larger studies will be needed to confirm the promise seen in this small group. Even so, the trial marks a joyful step forward for lupus research—and a deeply meaningful sign of possibility for patients facing a difficult disease.